Perimenopause Anxiety

Is Anxiety a Symptom of Perimenopause?

Many women are caught off guard by anxiety in their 40s: a racing heart at night, a sense of dread that seems to come from nowhere, or panic in situations that never used to bother them. Anxiety is common around the menopause transition, and research shows the risk of new anxiety can rise during this time, even for women who were never anxious before.

That said, perimenopause does not cause anxiety for everyone, and anxiety in midlife can also come from other health conditions. Here is what the research shows and what helps.

How Common Is Anxiety in Perimenopause?

  • A 2026 meta-analysis of 102 studies and more than 1.1 million women found anxiety symptoms in about 29% of perimenopausal women and 39% of postmenopausal women. Estimates varied widely, and rates were higher in studies that used screening questionnaires rather than diagnostic interviews.
  • The same review concluded that nearly 1 in 3 women have depressive, anxiety and/or insomnia symptoms around the menopause transition.
  • In UK primary care records, women ages 45 to 54 were diagnosed with anxiety at nearly twice the rate of men the same age.

Not all research agrees. A 2012 systematic review of older studies found anxiety levels were generally low through the transition and said there was not enough evidence to call “menopausal anxiety” a distinct disorder. Newer and larger studies suggest a real rise in risk, but how big it is depends on how anxiety is measured.

Who Is Most Likely to Develop It?

The Study of Women’s Health Across the Nation (SWAN), which followed nearly 3,000 U.S. women for 10 years, found something many people don’t expect:

  • Women with low anxiety before the transition were about 1.6 times more likely to have high anxiety symptoms during early or late perimenopause or after menopause. This was true even after accounting for stressful life events, financial strain, health and hot flashes.
  • Women who already had high anxiety tended to stay anxious, but their risk did not rise further with each stage.

In other words, perimenopause may be a time when anxiety appears for the first time, not just a time when existing anxiety gets worse.

Other factors linked to higher risk include:

  • Past trauma. In a study of women veterans ages 45 to 64, military sexual trauma was linked to nearly 5 times the odds of significant anxiety.
  • A history of PMDD. Researchers who study reproductive mood disorders say women with past or current PMDD may be especially sensitive to the hormone drop of late perimenopause and should be watched for worsening symptoms.
  • Hormone variability. Mood and hot flashes tend to be worse when hormone levels swing more, rather than being simply high or low.

Hot Flashes, Heart Palpitations and Sleep

Hot Flashes

Hot flashes can feel a lot like anxiety, with sweating, a pounding heart and a sense of alarm. Research shows a clear link between hot flashes and depressive symptoms, but a 2024 systematic review rated the evidence linking hot flashes to anxiety as very low certainty. Hot flashes and anxiety often happen together, but it is not proven that one causes the other.

Heart Palpitations

Palpitations, a racing, pounding or irregular heartbeat, are common in midlife. In a study of 394 women ages 40 to 59:

  • About 41% reported moderate or severe palpitations.
  • Palpitations were linked to both hot flashes and anxiety, and not to caffeine, alcohol or detected arrhythmia in that group.

A smaller study using heart monitors found that women with palpitations had measurable differences in heart rhythm. So palpitations shouldn’t be written off as “just anxiety.” If you have them, especially with chest pain, shortness of breath, dizziness or fainting, see a doctor, who may order an ECG.

Sleep

Sleep problems are common after menopause, even in women without hot flashes, and are linked to anxiety and depression. Researchers note that poor sleep predicts mood problems more strongly than hot flashes do.

Other Causes to Rule Out

Anxiety in midlife is worth a medical check, because other conditions can cause or worsen it:

  • Overactive thyroid. Graves’ disease raised the risk of anxiety disorders by about 50% in a large national study, and hyperthyroidism is a well-known cause of anxiety. About 1 in 10 midlife women in SWAN had an abnormal thyroid test.
  • Heart rhythm problems, especially if palpitations are frequent or come with other symptoms.
  • Caffeine. At about 5 cups of coffee, caffeine can trigger panic attacks in people prone to panic and raises anxiety even in healthy adults.
  • Iron deficiency, which has been linked to anxiety even without anemia. Heavy or irregular bleeding in perimenopause can lower iron.

Screening for Anxiety

The GAD-7 is a 7-question anxiety screener you can take in a few minutes. Scores of 5, 10 and 15 are commonly used for mild, moderate and severe symptoms. These cutoffs were validated in other groups, including pregnant and postpartum women, but not specifically in perimenopausal women, so use the result as a starting point for a conversation with your doctor.

Treatment for Perimenopausal Anxiety

Therapy

  • Cognitive behavioral therapy (CBT) designed for menopause improved hot flash interference, depression and sleep in a randomized trial. The researchers said more study is needed to confirm its effect on anxiety.
  • A small trial of a CBT program for perimenopausal women found greater improvement in GAD-7 anxiety scores than usual care.
  • Mindfulness-based stress reduction reduced anxiety, stress and depressive symptoms and improved sleep in a randomized trial of perimenopausal women, and lowered GAD-7 scores in a trial of menopausal women with anxiety disorder.

Find a therapist who treats anxiety and women’s mental health

Antidepressants

SSRIs and SNRIs are standard treatments for anxiety disorders, and The Menopause Society lists them among the best-supported nonhormonal treatments for hot flashes. The research specifically on perimenopausal anxiety is mixed: some trials found benefits for mood and menopause symptoms, while others found no advantage over placebo, and one trial using the GAD-7 found no change in a group with low anxiety to begin with. Your prescriber can help weigh the options.

Hormone Therapy

  • Hormone therapy is the most effective treatment for hot flashes, and The Menopause Society considers its benefits greater than its risks for most healthy women under 60 or within 10 years of menopause. That recommendation is for hot flashes and bone health, not anxiety.
  • In the KEEPS trial, oral conjugated estrogen modestly improved anxiety and depression symptoms over four years in recently postmenopausal women, while an estradiol patch did not.

Hormone therapy is not approved as an anxiety treatment. Whether it makes sense for you depends on your symptoms and health history.

Exercise

A meta-analysis of 21 trials found physical activity reduced both depression and anxiety symptoms in midlife women, though the anxiety benefit was clearest in women who were already postmenopausal. Mind-body exercise such as yoga and tai chi performed well in another analysis.

Supplements

  • Black cohosh did not reduce anxiety compared with placebo in the only trial that tested it for menopausal anxiety disorder, and it did not beat placebo for hot flashes in a large trial. There are reports of liver injury, though whether black cohosh caused them is debated.
  • The Menopause Society does not recommend supplements or herbal remedies for hot flashes.

Talk to your doctor or pharmacist before taking any supplement, especially if you take other medications.

When to Get Help

See your doctor if anxiety or panic is frequent, affects your sleep, work or relationships, or comes with low mood. Get medical care right away for chest pain, fainting or severe shortness of breath.

If you have thoughts of harming yourself, call or text 988 for the Suicide & Crisis Lifeline. Learn about perimenopause depression, which often occurs alongside anxiety.

Frequently Asked Questions

Can perimenopause cause anxiety?

Perimenopause is linked to a higher risk of anxiety. In a large U.S. study, women who weren’t anxious before the transition were about 1.6 times more likely to develop high anxiety during it.

Can perimenopause cause panic attacks?

Some women experience panic attacks for the first time in midlife, but there is no reliable figure for how common they are. Hot flashes, palpitations and caffeine can all trigger panic-like symptoms.

Are heart palpitations in perimenopause anxiety?

They can be linked to anxiety and hot flashes, but they can also reflect heart rhythm changes. Palpitations should be checked by a doctor.

Does HRT help anxiety?

It may help some women, and one large trial found modest improvement with oral estrogen, but hormone therapy is not an approved anxiety treatment. Therapy and antidepressants are standard treatments.

How long does perimenopause anxiety last?

It varies. Anxiety can continue after menopause, and in one review it was even more common postmenopause. Treatment helps regardless of stage.

PostpartumDepression.org Team
Written by:

Jenna Carberg was diagnosed with postpartum depression following the birth of her daughter in 2016. It was a healthy birth but in the following days, Jenna's mood changed quickly. Doctors suggested that it might be the "baby blues", but her husband Chris suggested she seek a second opinion. Jenna was diagnosed with postpartum depression and began a journey that lasted 9 long months with significant ups and downs. Jenna's mental health care and her experiences became a passion for her to share with the world. She and her husband Chris founded PostpartumDepression.org as a support website designed to help women suffering in silence and their loved ones.

  1. Balasubramanian I, Abhijita B, Krishnamoorthy Y, Gnanadhas J, Beg MJ, Menon V. “Prevalence and incidence of depressive, anxiety, and insomnia symptoms in perimenopausal and postmenopausal women: Systematic review and meta-analysis.” General Hospital Psychiatry. 2026;100:325-335. https://doi.org/10.1016/j.genhosppsych.2026.03.010.
  2. Bromberger JT, Kravitz HM, Chang Y, Randolph JF Jr, Avis NE, Gold EB, Matthews KA. “Does risk for anxiety increase during the menopausal transition? Study of women’s health across the nation.” Menopause. 2013;20(5):488-495. https://doi.org/10.1097/GME.0b013e3182730599.
  3. Bryant C, Judd FK, Hickey M. “Anxiety during the menopausal transition: a systematic review.” Journal of Affective Disorders. 2012;139(2):141-148. https://doi.org/10.1016/j.jad.2011.06.055.
  4. Neda-Stepan O, Enătescu VR, Giurgi-Oncu C, Bernad ES, Neamțu R, Bernad BC, Kadaș AV, Bredicean C. “Vasomotor Symptoms and Their Association with Depressive and Anxiety Symptoms in Peri- and Postmenopausal Women: A Systematic Review of Observational Studies.” Medicina (Kaunas). 2026;62(8):1574. https://doi.org/10.3390/medicina62081574.
  5. Enomoto H, Terauchi M, Odai T, Kato K, Iizuka M, Akiyoshi M, Miyasaka N. “Independent association of palpitation with vasomotor symptoms and anxiety in middle-aged women.” Menopause. 2021;28(7):741-747. https://doi.org/10.1097/GME.0000000000001776.
  6. Carpenter JS, Jaynes HA, Alzahrani MA, Chen PS, Kovacs RJ, Tisdale JE. “Palpitations in midlife women: the Menopause Racing Heart Pilot Study.” Menopause. 2025;32(7):571-582. https://doi.org/10.1097/GME.0000000000002538.
  7. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of Women’s Health Across the Nation. “Duration of menopausal vasomotor symptoms over the menopause transition.” JAMA Internal Medicine. 2015;175(4):531-539. https://doi.org/10.1001/jamainternmed.2014.8063.
  8. Santoro N. “Perimenopause: From Research to Practice.” Journal of Women’s Health. 2016;25(4):332-339. https://doi.org/10.1089/jwh.2015.5556.
  9. Sowers M, Luborsky J, Perdue C, Araujo KL, Goldman MB, Harlow SD; SWAN. “Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN.” Clinical Endocrinology. 2003;58(3):340-347. https://doi.org/10.1046/j.1365-2265.2003.01718.x.
  10. Lee JY, Hong M, Jung YH, Sohn SY. “Risk of psychiatric disorders in patients with graves’ disease: A nationwide population-based analysis.” Journal of Affective Disorders. 2025;385:119386. https://doi.org/10.1016/j.jad.2025.119386.
  11. Alci D, Eroglu M, Asik M. “Temperament Traits as Key Modulators of Depression and Anxiety in Hyperthyroidism: Implications for Personalized Treatment.” Cureus. 2025;17(3):e81503. https://doi.org/10.7759/cureus.81503.
  12. Culpepper L. “Generalized anxiety disorder and medical illness.” The Journal of Clinical Psychiatry. 2009;70 Suppl 2:20-24. https://doi.org/10.4088/jcp.s.7002.04.
  13. Klevebrant L, Frick A. “Effects of caffeine on anxiety and panic attacks in patients with panic disorder: A systematic review and meta-analysis.” General Hospital Psychiatry. 2022;74:22-31. https://doi.org/10.1016/j.genhosppsych.2021.11.005.
  14. Fiani D, Chahine S, Zaboube M, Solmi M, Powers JM, Calarge C. “Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: A meta-analysis and systematic review.” Neuroscience and Biobehavioral Reviews. 2025;178:106372. https://doi.org/10.1016/j.neubiorev.2025.106372.
  15. Lugo T, Tetrokalashvili M. “Hot Flashes.” StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. https://www.ncbi.nlm.nih.gov/books/NBK539827/. Accessed September 15, 2026.
  16. American College of Obstetricians and Gynecologists. “Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4.” Obstetrics & Gynecology. 2023;141(6):1232-1261. https://doi.org/10.1097/AOG.0000000000005200. (Reused from held corpus; perinatal guideline, not perimenopause-specific — see dossier §5.)
  17. Simpson W, Glazer M, Michalski N, Steiner M, Frey BN. “Comparative efficacy of the generalized anxiety disorder 7-item scale and the Edinburgh Postnatal Depression Scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period.” Canadian Journal of Psychiatry. 2014;59(8):434-440. https://doi.org/10.1177/070674371405900806. (Reused from held corpus; perinatal sample, not perimenopausal.)
  18. Kim DS, Kim NY, Han DH, Kim HJ, Yu ES, Kim SM. “Efficacy of cognitive behavioral therapy for menopausal symptoms and quality of life in Korean perimenopausal women: A pilot randomized controlled trial.” Maturitas. 2024;189:108103. https://doi.org/10.1016/j.maturitas.2024.108103.
  19. Green SM, Donegan E, Frey BN, Fedorkow DM, Key BL, Streiner DL, McCabe RE. “Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial.” Menopause. 2019;26(9):972-980. https://doi.org/10.1097/GME.0000000000001363.
  20. El-Monshed AH, Khonji LM, Altheeb M, Saad MTE, Elsheikh MA, Loutfy A, Ali AS, El-Gazar HE, Fayed SM, Zoromba MA. “Does a program-based cognitive behavioral therapy affect insomnia and depression in menopausal women? A randomized controlled trial.” Worldviews on Evidence-Based Nursing. 2024;21(2):202-215. https://doi.org/10.1111/wvn.12707.
  21. Gordon JL, Halleran M, Beshai S, Eisenlohr-Moul TA, Frederick J, Campbell TS. “Endocrine and psychosocial moderators of mindfulness-based stress reduction for the prevention of perimenopausal depressive symptoms: A randomized controlled trial.” Psychoneuroendocrinology. 2021;130:105277. https://doi.org/10.1016/j.psyneuen.2021.105277.
  22. Huang S, Wang Z, Zheng D, Liu L. “Anxiety disorder in menopausal women and the intervention efficacy of mindfulness-based stress reduction.” American Journal of Translational Research. 2023;15(3):2016-2024. https://pubmed.ncbi.nlm.nih.gov/37056841/.
  23. Yue H, Yang Y, Xie F, Cui J, Li Y, Si M, Li S, Yao F. “Effects of physical activity on depressive and anxiety symptoms of women in the menopausal transition and menopause: a comprehensive systematic review and meta-analysis of randomized controlled trials.” International Journal of Behavioral Nutrition and Physical Activity. 2025;22(1):13. https://doi.org/10.1186/s12966-025-01712-z.
  24. Han B, Duan Y, Zhang P, Zeng L, Pi P, Chen J, Du G. “Effects of exercise on depression and anxiety in postmenopausal women: a pairwise and network meta-analysis of randomized controlled trials.” BMC Public Health. 2024;24(1):1816. https://doi.org/10.1186/s12889-024-19348-2.
  25. Alsugeir D, Adesuyan M, Talaulikar V, Wei L, Whittlesea C, Brauer R. “Common mental health diagnoses arising from or coinciding with menopausal transition and prescribing of SSRIs/SNRIs medications and other psychotropic medications.” Journal of Affective Disorders. 2024;364:259-265. https://doi.org/10.1016/j.jad.2024.08.036.
  26. Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. “Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.” The Journal of the Oklahoma State Medical Association. 2017;110(5):272-274. https://pubmed.ncbi.nlm.nih.gov/28649145/.
  27. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. “Efficacy of citalopram on climacteric symptoms.” Menopause. 2007;14(2):223-229. https://doi.org/10.1097/01.gme.0000243571.55699.4a.
  28. Suvanto-Luukkonen E, Koivunen R, Sundström H, Bloigu R, Karjalainen E, Häivä-Mällinen L, Tapanainen JS. “Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study.” Menopause. 2005;12(1):18-26. https://doi.org/10.1097/00042192-200512010-00006.
  29. Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE. “Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years.” Psychosomatics. 2005;46(4):345-354. https://doi.org/10.1176/appi.psy.46.4.345.
  30. Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, Cohen LS, Freeman EW, Manson JE, Newton K, Reed S, Rexrode K, Shifren J, Sternfeld B, Ensrud K. “Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.” Menopause. 2015;22(6):607-615. https://doi.org/10.1097/GME.0000000000000364.
  31. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. “The 2022 hormone therapy position statement of The North American Menopause Society.” Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028.
  32. Nappi RE. “The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news.” The Lancet Diabetes & Endocrinology. 2022;10(12):832-834. https://doi.org/10.1016/S2213-8587(22)00285-6.
  33. The North American Menopause Society. “The 2023 nonhormone therapy position statement of The North American Menopause Society.” Menopause. 2023;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200.
  34. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. “Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.” PLoS Medicine. 2015;12(6):e1001833. https://doi.org/10.1371/journal.pmed.1001833.
  35. Le Y, Li X, Guo X, Seo JE, Manjanatha MG, Mei N. “Review of black cohosh-induced toxicity and adverse clinical effects.” Journal of Environmental Science and Health, Part C. 2025;43(3):243-268. https://doi.org/10.1080/26896583.2025.2513795.
  36. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. “Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.” Menopause. 2011;18(4):366-375. https://doi.org/10.1097/gme.0b013e3181fcb2a6. (Industry-funded; see dossier §10 and Contested.)
  37. Mahady G, Low Dog T, Sarma DN, Giancaspro GI. “Suspected black cohosh hepatotoxicity–causality assessment versus safety signal.” Maturitas. 2009;64(2):139-142. https://doi.org/10.1016/j.maturitas.2009.08.015.
  38. Amsterdam JD, Yao Y, Mao JJ, Soeller I, Rockwell K, Shults J. “Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause.” Journal of Clinical Psychopharmacology. 2009;29(5):478-483. https://doi.org/10.1097/JCP.0b013e3181b2abf2.
  39. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. “Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.” Annals of Internal Medicine. 2006;145(12):869-879. https://doi.org/10.7326/0003-4819-145-12-200612190-00003.
  40. Sander B, Gordon JL. “Premenstrual Mood Symptoms in the Perimenopause.” Current Psychiatry Reports. 2021;23(11):73. https://doi.org/10.1007/s11920-021-01285-1.
  41. Rapkin AJ, Mikacich JA, Moatakef-Imani B, Rasgon N. “The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders.” Current Psychiatry Reports. 2002;4(6):419-428. https://doi.org/10.1007/s11920-002-0069-7.
  42. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. “Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.” The New England Journal of Medicine. 1998;338(4):209-216. https://doi.org/10.1056/NEJM199801223380401. (Reused from held corpus; studied premenstrual syndrome, not perimenopause — see dossier §11.)
  43. Miller C, Carlson K. “Premenstrual Disorders.” StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated August 9, 2026. https://www.ncbi.nlm.nih.gov/books/NBK532307/. Accessed September 15, 2026. (Reused from held corpus.)
  44. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. “Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition.” Menopause. 2016;23(3):257-266. https://doi.org/10.1097/GME.0000000000000528.
  45. Soares CN, Frey BN. “Challenges and opportunities to manage depression during the menopausal transition and beyond.” The Psychiatric Clinics of North America. 2010;33(2):295-308. https://doi.org/10.1016/j.psc.2010.01.007.
  46. Frey BN, Lord C, Soares CN. “Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates.” Menopause International. 2008;14(3):123-128. https://doi.org/10.1258/mi.2008.008019.
  47. Bonanni E, Schirru A, Di Perri MC, Bonuccelli U, Maestri M. “Insomnia and hot flashes.” Maturitas. 2019;126:51-54. https://doi.org/10.1016/j.maturitas.2019.05.001.
  48. Brown JP, Gallicchio L, Flaws JA, Tracy JK. “Relations among menopausal symptoms, sleep disturbance and depressive symptoms in midlife.” Maturitas. 2009;62(2):184-189. https://doi.org/10.1016/j.maturitas.2008.11.019.
  49. Soares CN, Bajbouj M, Schoof N, Kishore A, Caetano C. “Impact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review.” Menopause. 2026;33(1):118-128. https://doi.org/10.1097/GME.0000000000002633.
  50. Travis KJ, Huang AJ, Maguen S, Inslicht S, Byers AL, Seal KH, Gibson CJ. “Military Sexual Trauma and Menopause Symptoms Among Midlife Women Veterans.” Journal of General Internal Medicine. 2024;39(3):411-417. https://doi.org/10.1007/s11606-023-08493-w.
  51. Allshouse A, Pavlovic J, Santoro N. “Menstrual Cycle Hormone Changes Associated with Reproductive Aging and How They May Relate to Symptoms.” Obstetrics and Gynecology Clinics of North America. 2018;45(4):613-628. https://doi.org/10.1016/j.ogc.2018.07.004.